Selective ETA receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima formation in the rat.
Cardiovasc Res
; 29(5): 641-6, 1995 May.
Article
em En
| MEDLINE
| ID: mdl-7606751
ABSTRACT
OBJECTIVE:
The aim was to assess whether or not the endothelin ETA receptor selective antagonist BQ-123 could inhibit neointima formation in vivo following balloon angioplasty.METHODS:
The effect of either acute administration of BQ-123 (0.1 mg.kg-1.min-1 intra-arterial infusion for 1 h before and 1 h after angioplasty) or chronic administration (bolus intraperitoneal injection, 2.5 mg.kg-1 twice daily; continuous intraperitoneal infusion, 0.8 and 8 mg.kg-1.d-1) on neointima formation was examined in rats which had undergone left common carotid artery balloon angioplasty.RESULTS:
Neither acute intra-arterial infusion nor either mode of chronic intraperitoneal administration of BQ-123 had a significant effect on the degree of neointima formation observed following balloon angioplasty.CONCLUSIONS:
Neither acute nor chronic ETA receptor blockade is sufficient to inhibit angioplasty induced neointima formation in the rat. Since it was previously shown that the ETA/B antagonist SB 209670 was effective in this model, while the ETA selective antagonist BQ-123 is now found to be ineffective, the data implicate the ETB receptor subtype in the pathogenesis of neointima formation.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Peptídeos Cíclicos
/
Estenose das Carótidas
/
Túnica Íntima
/
Angioplastia com Balão
/
Antagonistas dos Receptores de Endotelina
Limite:
Animals
Idioma:
En
Ano de publicação:
1995
Tipo de documento:
Article